Follistatin
A natural protein that blocks myostatin — your body's built-in limit on how much muscle you can grow. Think of myostatin as the 'brake pedal' for muscle growth; follistatin takes that brake off, allowing muscles to grow beyond their normal limit. This is the same mechanism behind those incredibly muscular cattle breeds. Available as FS344 (the most common form). Short cycles are recommended because it also affects fertility hormones.
Dosage
100-300 mcg subcutaneous once daily (short cycles of 10-30 days)
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Myostatin Inhibition
Binds and neutralizes myostatin with picomolar affinity — removes the brake on muscle growth.
Muscle Growth Potential
Blocking myostatin allows unrestricted myogenic differentiation and protein synthesis.
Mechanism of Action
Follistatin is a naturally occurring monomeric glycoprotein produced by virtually all tissues, with particularly high expression in the liver, ovaries, and skeletal muscle. It functions as a high-affinity binding protein for several members of the TGF-beta superfamily, most importantly myostatin (GDF-8) and activin A/B. By binding these ligands with picomolar affinity, follistatin sequesters them in inactive complexes and prevents them from engaging their cell-surface receptors.
Myostatin is the primary endogenous negative regulator of skeletal muscle mass. It signals through the activin type IIB receptor (ActRIIB), which recruits and activates the type I receptor ALK4/5, initiating Smad2/3 phosphorylation. Phosphorylated Smad2/3 complexes with Smad4, translocates to the nucleus, and suppresses the expression of myogenic transcription factors MyoD, myogenin, and Myf5 — directly inhibiting satellite cell differentiation, muscle protein synthesis, and myofibrillar growth. By neutralizing myostatin, follistatin removes this molecular brake, allowing the myogenic program to proceed unchecked.
Follistatin exists in multiple isoforms with distinct tissue distributions. Follistatin 315 (FS315) contains a heparan sulfate proteoglycan-binding domain that anchors it to cell surfaces and local tissue, making it a paracrine factor. Follistatin 344 (FS344) lacks this anchoring domain and circulates freely in the bloodstream, acting as an endocrine factor. FS344 is the commercially available form and, upon injection, is cleaved to FS315 and FS303 in circulation. Beyond myostatin, follistatin's neutralization of activin has broader endocrine effects — activin is a critical stimulator of FSH production in the pituitary, which is why follistatin also functions as a reproductive hormone regulator. This multi-target activity means exogenous follistatin administration could potentially affect fertility and other TGF-beta-mediated processes.
Regulatory Status
Not FDA approved. Research compound. Gene therapy approaches using follistatin are in early clinical trials for muscular dystrophy.
Risks & Safety
Common
injection site reactions, mild tiredness.
Serious
can disrupt reproductive hormones and fertility by blocking activin (a key regulator of FSH), potential long-term fertility impairment.
Rare
impaired wound healing, allergic reactions.
Compare Follistatin With
Research Papers
30Published: January 19, 2026
AI Summary
Liraglutide's early effects on body composition and circulating muscle and bone regulators like myostatin, activin, follistatin, and IGF-1 were assessed in a crossover trial. The work clarifies how GLP-1 drugs affect muscle and bone metabolism in the first weeks of treatment.
Published: January 6, 2026
AI Summary
FSTL1 in the brain acts as an insulin sensitizer, and targeting it reduced weight gain and improved blood sugar in mice. Boosting brain insulin signaling through FSTL1 may be a useful strategy against obesity and related metabolic disease.
Published: December 28, 2025
AI Summary
Blocking myostatin, including with follistatin-based approaches, increases muscle mass and function in preclinical and early clinical studies. The review outlines how these therapies could address age-related muscle loss and the hurdles to bringing them to patients.
Published: February 15, 2026
AI Summary
Treadmill exercise protects the heart after heart attack by activating Piezo1, which reduces cell death and fibrosis and drives FSTL1 and GDF5. Piezo1 appears to be a key sensor linking exercise to heart protection.
Published: December 10, 2025
AI Summary
A microRNA (miR-299a-5p) promotes diabetic kidney fibrosis by suppressing follistatin and cripto-1, which unleashes activin and TGF-beta signaling. Blocking this microRNA improved kidney disease markers in mice and raised follistatin and cripto-1 levels.
Published: December 7, 2025
AI Summary
In aged female rats, HIIT raised muscle follistatin more than resistance training, while resistance training raised myostatin more. HIIT may be a better option for older adults aiming to improve the follistatin-myostatin balance.
Published: February 1, 2026
AI Summary
Head and neck tumors produce myostatin, activin-A, and follistatin, which may drive muscle loss in cancer. The exploratory study links these factors to sarcopenia in HNC patients.
Published: December 24, 2025
AI Summary
Lowering FSTL1 protected kidney cells from sepsis-related iron-dependent cell death by turning on PI3K/Akt signaling. Targeting FSTL1 could be a new way to limit kidney injury in sepsis.
Published: February 23, 2026
AI Summary
Short-term liraglutide changed metabolic measures, body composition, and the myostatin-activin-follistatin-IGF-1 axis in people with type 2 diabetes. The exploratory study clarifies when and where these effects appear.
Published: November 23, 2025
AI Summary
Fructose and follistatin can trigger fatty liver even when the liver is fully insulin resistant. In humans, higher blood follistatin was linked to more liver fat and adipose insulin resistance, suggesting follistatin as a target in fatty liver disease.
Published: November 28, 2025
AI Summary
Exercise intensity influenced blood levels of CTRP3, CTRP9, and FSTL1, which are linked to metabolic health. The work explores why high-intensity exercise may confer greater metabolic benefits than moderate-intensity.
Published: January 22, 2026
AI Summary
FSTL-1, FAM19A5, and CTRP-6 were measured in overweight children to explore their link to metabolic markers and obesity. Understanding these adipokines could clarify how obesity drives metabolic dysfunction in youth.
Published: November 5, 2025
AI Summary
Cardiac rehab changed circulating myostatin, follistatin, apelin, and FSTL1 in heart attack patients, with different patterns for STEMI vs. NSTEMI. These myokine shifts may partly explain the benefits of rehab and support tailored programs.
Published: November 3, 2025
AI Summary
Low FABP4 predicted coronary artery disease, while FSTL1, irisin, and adiponectin together identified metabolic syndrome with high accuracy. These organokines may help diagnose and personalize treatment for heart and metabolic disease.
Published: September 24, 2025
AI Summary
Glaucoma was linked to higher ET-1 and several aqueous humor proteins including follistatin, with MMP-3, ZAG, and APN tied to reduced blood flow. These markers may help assess glaucoma risk and perfusion.
Published: October 15, 2025
AI Summary
Goose follistatin influences both muscle development and fat metabolism, affecting stem cell markers, myogenic regulators, and lipid pathways. The findings clarify how follistatin shapes muscle growth in poultry.
Published: January 6, 2026
AI Summary
Brain FSTL1 counters diet-induced obesity by enhancing insulin signaling and blocking FoxO1. Intranasal FSTL1 promoted weight loss and improved insulin sensitivity in obese mice, suggesting a potential obesity treatment.
Published: October 14, 2025
AI Summary
The axon cue SLIT2, via sympathetic nerves, controls bone stem cell behavior, and FSTL1 suppresses their self-renewal. Blocking FSTL1 in sympathetic neurons improved bone formation and partly reversed bone loss in mice.
Published: December 10, 2025
AI Summary
Neuronal FSTL4 limits BDNF-driven support of glioma growth. Boosting FSTL4 in neurons reduced tumor support, suggesting that activating FSTL4 could be a new strategy for glioma treatment.
Published: October 19, 2025
AI Summary
Cancer cachexia damages the pancreas via activin A signaling. The work explores how this pathway contributes to pancreatic injury in ovarian cancer-associated wasting.
Published: September 24, 2025
AI Summary
Levamisole given at breeding changed immune and hormone profiles in ewes without affecting pregnancy rates. The work explores how immunomodulators influence activin, follistatin, and other markers during early pregnancy.
Published: September 2, 2025
AI Summary
COVID-19 alters muscle and bone markers including myostatin, IGF-1, and follistatin, which may explain post-COVID muscle loss. The review highlights how these biomarkers could guide early detection and treatment of musculoskeletal complications.
Published: August 22, 2025
AI Summary
Myokines like follistatin-like 1, myostatin, and irisin influence heart disease and heart failure. The review focuses on their role in rheumatoid arthritis patients, who have higher cardiovascular risk and altered myokine levels.
Published: May 12, 2025
AI Summary
Activin A levels in sputum and blood were tracked during flare-ups and recovery in COPD, asthma, and ACO. The work explores how the activin-follistatin axis behaves during exacerbations and whether it predicts recurrent flares.
Published: August 17, 2025
AI Summary
Two gut bacteria, Lactobacillus johnsonii and Limosilactobacillus reuteri, increased muscle strength in aged mice by raising follistatin and IGF-1 in muscle. The findings show that specific microbes can directly improve muscle function.
Published: July 28, 2025
AI Summary
Mouse and sheep GnRH receptor genes respond differently to follistatin and activin. Follistatin doubled promoter activity in sheep but reduced it in mice, showing species-specific regulation of reproductive signaling.
Published: November 4, 2025
AI Summary
BDNF, FSTL1, and FABP3 changed over time in burn patients during physiotherapy. These myokines may track rehabilitation and recovery and could inform strategies to prevent muscle wasting in critically ill patients.
Published: June 14, 2025
AI Summary
Irisin, myostatin, follistatin, and BDNF show promise as biomarkers for age-related muscle loss, though results vary and some studies report no link. More work is needed to define cutoff values and validate their use in clinical practice.
Published: June 25, 2025
AI Summary
In people with fatty liver and obesity, higher follistatin was linked to lower PAI-1 after a plant-based diet, suggesting follistatin may dampen clotting risk. The two markers may work together to regulate prothrombotic status.
Published: July 7, 2025
AI Summary
A score combining CXCL9, GDF15, FGF21, and NfL predicted long-term death in type 2 diabetes. The work evaluates biomarkers of inflammation, metabolic stress, and organ damage for risk stratification.
Frequently Asked Questions
What is Follistatin?
A natural protein that blocks myostatin — your body's built-in limit on how much muscle you can grow. Think of myostatin as the 'brake pedal' for muscle growth; follistatin takes that brake off, allowing muscles to grow beyond their normal limit. This is the same mechanism behind those incredibly muscular cattle breeds. Available as FS344 (the most common form). Short cycles are recommended because it also affects fertility hormones.
What is Follistatin used for?
A natural protein that blocks myostatin — your body's built-in limit on how much muscle you can grow. Think of myostatin as the 'brake pedal' for muscle growth; follistatin takes that brake off, allowing muscles to grow beyond their normal limit. This is the same mechanism behind those incredibly muscular cattle breeds. Available as FS344 (the most common form). Short cycles are recommended because it also affects fertility hormones.
What is the dosage for Follistatin?
Research: 100-300 mcg subcutaneous once daily. Follistatin 344 is the most commonly available form. Short cycles of 10-30 days are typical. Extended use protocols are not established.
What are the side effects of Follistatin?
Common: injection site reactions, mild tiredness. Serious: can disrupt reproductive hormones and fertility by blocking activin (a key regulator of FSH), potential long-term fertility impairment. Rare: impaired wound healing, allergic reactions.
How does Follistatin work?
Follistatin is a naturally occurring monomeric glycoprotein produced by virtually all tissues, with particularly high expression in the liver, ovaries, and skeletal muscle. It functions as a high-affinity binding protein for several members of the TGF-beta superfamily, most importantly myostatin (GDF-8) and activin A/B. By binding these ligands with picomolar affinity, follistatin sequesters them in inactive complexes and prevents them from engaging their cell-surface receptors. Myostatin is the primary endogenous negative regulator of skeletal muscle mass. It signals through the activin type IIB receptor (ActRIIB), which recruits and activates the type I receptor ALK4/5, initiating Smad2/3 phosphorylation. Phosphorylated Smad2/3 complexes with Smad4, translocates to the nucleus, and suppresses the expression of myogenic transcription factors MyoD, myogenin, and Myf5 — directly inhibiting satellite cell differentiation, muscle protein synthesis, and myofibrillar growth. By neutralizing myostatin, follistatin removes this molecular brake, allowing the myogenic program to proceed unchecked. Follistatin exists in multiple isoforms with distinct tissue distributions. Follistatin 315 (FS315) contains a heparan sulfate proteoglycan-binding domain that anchors it to cell surfaces and local tissue, making it a paracrine factor. Follistatin 344 (FS344) lacks this anchoring domain and circulates freely in the bloodstream, acting as an endocrine factor. FS344 is the commercially available form and, upon injection, is cleaved to FS315 and FS303 in circulation. Beyond myostatin, follistatin's neutralization of activin has broader endocrine effects — activin is a critical stimulator of FSH production in the pituitary, which is why follistatin also functions as a reproductive hormone regulator. This multi-target activity means exogenous follistatin administration could potentially affect fertility and other TGF-beta-mediated processes.
How is Follistatin administered?
Follistatin is administered via subcutaneous injection.
What is the half-life of Follistatin?
The half-life of Follistatin is FS344: 4-6 hours | FS315: longer due to tissue binding.
Is Follistatin legal?
Not FDA approved. Research compound. Gene therapy approaches using follistatin are in early clinical trials for muscular dystrophy.
Related Peptides
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
BPC-157 + TB-500
A two-in-one product that pairs BPC-157 and TB-500 to target different healing pathways. BPC-157 focuses on gut, tendon, and ligament repair by supporting blood vessel growth and nitric oxide signaling, while TB-500 helps cells move to injury sites for body-wide tissue repair. The most popular peptide combination for healing and recovery.